GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Clover Health Investments Corp (NAS:CLOV) » Definitions » Research & Development

CLOV (Clover Health Investments) Research & Development : $0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clover Health Investments Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Clover Health Investments's Research & Development for the three months ended in Dec. 2024 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $0 Mil.

Clover Health Investments Research & Development Historical Data

The historical data trend for Clover Health Investments's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Health Investments Research & Development Chart

Clover Health Investments Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial - - - - -

Clover Health Investments Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Clover Health Investments Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clover Health Investments  (NAS:CLOV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Clover Health Investments Research & Development Related Terms

Thank you for viewing the detailed overview of Clover Health Investments's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Clover Health Investments Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Clover Health Investments Corp (NAS:CLOV) » Definitions » Research & Development
Comparable Companies
ALHC OSCR NEUE MRAI PFHO UNH ELV CI CVS HUM CNC MOH SZSE:000503 BSP:ODPV3 NSE:MEDIASSIST BJSE:870656 BSP:QUAL3 ROCO:6665 MIL:HI TSXV:NXG
Traded in Other Exchanges
7QD:Germany
Address
3401 Mallory Lane, Suite 210, Franklin, TN, USA, 37067
Website
https://www.cloverhealth.com
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. Operating in two segments, Insurance and Non-Insurance, Clover Health offers PPO and HMO plans to Medicare Advantage members in multiple states through its Insurance segment. In the Non-Insurance segment, the company participates in the ACO REACH Model. The majority of revenue is generated from the insurance segment, reflecting the significance of its healthcare insurance offerings.
Executives
Carladenise Armbrister Edwards director C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Vivek Garipalli director, 10 percent owner, officer: Executive Chairperson C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067
Anna U Loengard director C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Karen Soares officer: General Counsel & Secretary 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Clover Health Investments, Corp. /de officer: Chief Technology Officer 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Andrew Toy director, officer: Chief Executive Officer C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067
Scott J. Leffler officer: Chief Financial Officer C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Brady Patrick Priest officer: CEO of Home Care C/O CLOVER HEALTH INVESTMENTS, CORP., FRANKLIN TN 37067
Demetrios L. Kouzoukas director C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN FL 37067
Aric R Sharp officer: CEO of Value-Based Care C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Wai Conrad officer: Chief Technology Officer 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067
Joseph Richards Martin officer: General Counsel C/O LOUISIANA-PACIFIC CORPORATION, 414 UNION STREET, SUITE 2000, NASHVILLE TN 37219
Chelsea Clinton director C/O IAC 555 W 18TH STREET, NEW YORK NY 10011
Jamie L. Reynoso officer: CEO of Medicare Advantage C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067
Chamath Palihapitiya 10 percent owner, other: See Remarks THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025